Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eesti - eesti - Ravimiamet

accord healthcare b.v. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 10ml 1tk; 5mg 1ml 40ml 1tk; 5mg 1ml 20ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombootilised ained - duoplavin on näidustatud aterotrombootiliste sündmuste sekundaarseks ennetamiseks täiskasvanud patsientidel, kes juba kasutavad nii klopidogreeli kui ka atsetüülsalitsüülhapet (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. täiendava teabe jaoks vt osa 5.

Eesti - eesti - Ravimiamet

bayer ag - gadobutrool - süstelahus manustamissüsteemis - 1mmol 1ml 30ml 1tk; 1mmol 1ml 5ml 1tk; 1mmol 1ml 15ml 1tk

Eesti - eesti - Ravimiamet

bayer ag - gadobutrool - süstelahus - 1mmol 1ml 15ml 1tk; 1mmol 1ml 15ml 10tk; 1mmol 1ml 7.5ml 1tk; 1mmol 1ml 30ml 10tk; 1mmol 1ml 65ml 1tk; 1mmol 1ml 65ml 10tk

Eesti - eesti - Ravimiamet

bayer ag - gadobutrool - süstelahus - 1mmol 1ml 15ml 10tk; 1mmol 1ml 30ml 1tk; 1mmol 1ml 7.5ml 1tk; 1mmol 1ml 7.5ml 10tk

Eesti - eesti - Ravimiamet

bayer ag - gadobutrool - süstelahus süstlis - 1mmol 1ml 7.5ml 5tk; 1mmol 1ml 5ml 5tk; 1mmol 1ml 7.5ml 1tk; 1mmol 1ml 10ml 1tk; 1mmol 1ml 15ml 5tk

Eesti - eesti - Ravimiamet

woerwag pharma gmbh & co. kg - tiamiin+püridoksiin - süstelahus - 100mg+50mg 1ml 20tk; 100mg+50mg 1ml 5tk; 100mg+50mg 1ml 100tk

Eesti - eesti - Ravimiamet

bayer ag - jopromiid - süste-/infusioonilahus - 623mg 1ml 10ml 10tk; 623mg 1ml 50ml 10tk; 623mg 1ml 500ml 1tk; 623mg 1ml 500ml 8tk; 623mg 1ml 100ml 10tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - oksaliplatiin - infusioonilahuse kontsentraat - 5mg 1ml 20ml 1tk; 5mg 1ml 40ml 1tk; 5mg 1ml 10ml 1tk